Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

733 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets.
Agostinelli C, Morandi L, Righi S, Cirillo L, Iommi M, Tonon C, Mazzatenta D, Zoli M, Rossi M, Bagnato G, Broccoli A, Lodi R, Zinzani PL, Sabattini E, Giannini C, Asioli S. Agostinelli C, et al. Among authors: zinzani pl. Mod Pathol. 2023 Dec;36(12):100323. doi: 10.1016/j.modpat.2023.100323. Epub 2023 Sep 9. Mod Pathol. 2023. PMID: 37678673
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity.
Di Staso R, Casadei B, Gentilini M, Guadagnuolo S, Pellegrini C, Broccoli A, Gori D, Masetti R, Stefoni V, Bonifazi F, Zinzani PL, Argnani L. Di Staso R, et al. Among authors: zinzani pl. Ann Hematol. 2024 May 2. doi: 10.1007/s00277-024-05766-0. Online ahead of print. Ann Hematol. 2024. PMID: 38695872
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Le Gouill S, Długosz-Danecka M, Rule S, Zinzani PL, Goy A, Smith SD, Doorduijn JK, Panizo C, Shah BD, Davies AJ, Eek R, Jacobsen E, Kater AP, Robak T, Jain P, Calvo R, Tao L, Wang M. Le Gouill S, et al. Among authors: zinzani pl. Haematologica. 2024 Jan 1;109(1):343-350. doi: 10.3324/haematol.2022.282469. Haematologica. 2024. PMID: 37470152 Free PMC article. No abstract available.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: zinzani pl. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12. Ann Hematol. 2023. PMID: 37171597 Free PMC article.
Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma.
Kuipers MT, Spanjaart AM, Bonifazi F, diBlasi R, Zinzani PL, Thieblemont C, Baudet M, Biemond BJ, Kok WEM, Kersten MJ. Kuipers MT, et al. Among authors: zinzani pl. Leuk Lymphoma. 2024 Mar;65(3):399-402. doi: 10.1080/10428194.2023.2288804. Epub 2023 Dec 9. Leuk Lymphoma. 2024. PMID: 38069804 No abstract available.
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Crosswell HE, LaCasce AS, Bartlett NL, Straus DJ, Savage KJ, Zinzani PL, Collins GP, Fanale M, Fenton K, Dong C, Miao H, Grigg AP. Crosswell HE, et al. Among authors: zinzani pl. Haematologica. 2024 Mar 1;109(3):982-987. doi: 10.3324/haematol.2023.283303. Haematologica. 2024. PMID: 37794803 Free PMC article. No abstract available.
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: zinzani pl. Ann Hematol. 2023 Sep;102(9):2643-2644. doi: 10.1007/s00277-023-05321-3. Ann Hematol. 2023. PMID: 37432417 Free PMC article. No abstract available.
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Voltin CA, Paccagnella A, Winkelmann M, Heger JM, Casadei B, Beckmann L, Herrmann K, Dekorsy FJ, Kutsch N, Borchmann P, Fanti S, Kunz WG, Subklewe M, Kobe C, Zinzani PL, Stelljes M, Roth KS, Drzezga A, Noppeney R, Rahbar K, Reinhardt HC, von Tresckow B, Seifert R, Albring JC, Blumenberg V, Farolfi A, Flossdorf S, Gödel P, Hanoun C. Voltin CA, et al. Among authors: zinzani pl. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1361-1370. doi: 10.1007/s00259-023-06554-0. Epub 2023 Dec 20. Eur J Nucl Med Mol Imaging. 2024. PMID: 38114616 Free PMC article.
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Jimenez-Ubieto A, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Nunes A, Reitan J, Wade SW, Salles G. Hess G, et al. Among authors: zinzani pl. Leuk Lymphoma. 2024 Jan;65(1):14-25. doi: 10.1080/10428194.2023.2268228. Epub 2024 Jan 10. Leuk Lymphoma. 2024. PMID: 37840282
Novel therapies for aggressive B-cell lymphoma.
Foon KA, Takeshita K, Zinzani PL. Foon KA, et al. Among authors: zinzani pl. Adv Hematol. 2012;2012:302570. doi: 10.1155/2012/302570. Epub 2012 Mar 25. Adv Hematol. 2012. PMID: 22536253 Free PMC article.
733 results